Clinical trials: Patient With Schizophrenia Spectrum Disorder
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Schizophrenia
Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
The study aims to investigate the modulation of regional brain activation in schizophrenic patients by psychopharmacological treatment with either haloperidol, amisulpride or olanzapine.
- Trial name
- NCT00419653
- Testing
- Amisulpride, Olanzapine, Haloperidol
- Volunteers
- 19 people
- Sponsor
- University of Jena
Schizophrenia
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
- Trial name
- NCT01412060
- Testing
- Cariprazine
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 765 people
- Sponsor
- Forest Laboratories
Schizophrenia, Schizoaffective Disorder
Effectiveness of Ziprasidone for Patients With Schizophrenia
This study is designed with the aim to evaluate the clinical effect of the overlapped switching to ziprasidone as well as the efficacy and safe metabolic profile of ziprasidone.
- Trial name
- NCT01198353
- Testing
- Ziprasidone
- Where
- 6 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- Soonchunhyang University Hospital
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
Clinical Trial of Tolcapone for Cognition in Schizophrenia
This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the…
- Trial name
- NCT00044083
- Testing
- Tolcapone
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia
The aim of this study is to compare the efficacy of a flexible high dose of lurasidone to a standard dose of lurasidone in patients with treatment resistant schizophrenia or schizoaffective disorder.
- Trial name
- HDL (NCT01569659)
- Testing
- Lurasidone
- Where
- 2 sites in United States
- Volunteers
- 101 people
- Sponsor
- Northwestern University
Schizophrenia, Schizoaffective Disorder
Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness
Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- Wellness (NCT00661869)
- Testing
- Wellness Program
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of…
- Trial name
- NCT00261430
- Testing
- GAIN Acceptance Approach
- Volunteers
- 650 people
- Sponsor
- Janssen, LP
Schizophrenia, Bipolar I Disorder
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
The purpose of this study is to demonstrate the efficacy and safety of quetiapine fumarate (SEROQUEL) in the treatment of adolescent patients with schizophrenia and bipolar I disorder.
- Trial name
- ANCHOR 150 (NCT00227305)
- Testing
- quetiapine fumarate
- Where
- 48 sites in United States, India and 7 more
- Volunteers
- 381 people
- Sponsor
- AstraZeneca
Schizophrenia, Drug Abuse/Dependency
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Background: Individuals with schizophrenia have a significantly higher tendency to develop substance abuse or dependence than the general population.
- Trial name
- NCT01037075
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Schizophrenia
Treatment of Schizophrenic Patients With Ziprasidone
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
- Trial name
- TRITON (NCT00579670)
- Testing
- Ziprasidone
- Where
- 20 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Psychomotor Retardation, Psychomotor Slowing
Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor slowing may occur in major psychiatric disorders, such as major depressive disorders or schizophrenia spectrum disorders. It refers to slowing of fine motor skills, motor planning and gross motor behavior.
- Conditions
- Psychomotor Retardation, Psychomotor Slowing, Schizophrenia and Related Disorders, Major Depressive Disorder
- Trial name
- NCT03275766
- Testing
- DLPFC facilitatory, SMA inhibitory, SMA facilitatory
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- University of Bern
Schizophrenia, Schizoaffective Disorder
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or schizoaffective disorder, after switching…
- Trial name
- NCT00395031
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D
Schizophrenia
Amisulpride in Schizophrenic Patients
Primary purpose: To find out how effective is long term treatment with amisulpride on the positive and negative symptoms in schizophrenic patients To find out how safe is long term treatment with amisulpride in schizophrenic…
- Trial name
- NCT00331981
- Testing
- Amisulpride
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Sanofi
Schizophrenia, Neurocognitive Disorders
Goal Management Training for Patients With Schizophrenia or High Risk for Schizophrenia
About 85% of patients with schizophrenia have cognitive impairments, executive functions being particularly affected. Executive dysfunction, and cognitive deficits in general, are important predictors of functional outcomes…
- Trial name
- NCT03048695
- Testing
- GMT
- Where
- Norway
- Volunteers
- 83 people
- Sponsor
- Sykehuset Innlandet HF
Schizophrenia
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155.
- Trial name
- NCT06791122
- Testing
- Digital therapeutic (CT-155)
- Where
- 31 sites in United States
- Volunteers
- 262 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia, HIV Infections
The Quality of Life of Patients With Severe Illnesses
Lately researchers and clinicians have emphasized the health related quality of life. Several reasons account for this trend. First of all, the advanced medical practices have contributed to the increased life expectancy.
- Trial name
- NCT00173329
- Where
- Taiwan
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S